source
- Roivant's experimental pulmonary hypertension drug meets Phase 2 goalsRoivant announced that its experimental drug mosliciguat achieved the primary endpoint in a 16‑week Phase 2 trial for pulmonary hypertension, a serious lung condition. The study showed a 56% reduc…
- Amgen reports positive lung cancer trial results for Imdelltra combined with checkpoint inhibitorAmgen announced that its T-cell engager candidate Imdelltra, when used together with a checkpoint inhibitor, showed a clinical benefit in patients with advanced lung cancer. The trial data indicat…